Rexahn Pharmaceuticals to Present at 18th Annual Rodman & Renshaw Global Investment Conference on September 12, 2016
September 07, 2016 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the...
Rexahn Pharmaceuticals Reports Second Quarter 2016 Financial and Operational Results
August 08, 2016 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of...
Rexahn Pharmaceuticals Strengthens Leadership Team
July 11, 2016 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., July 11, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of...
Rexahn Pharmaceuticals Presents Clinical Data for Three Novel Targeted Oncology Programs at the 2016 American Society of Clinical Oncology Annual Meeting
June 06, 2016 09:02 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., June 06, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment...
Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
May 23, 2016 09:36 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., May 23, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment...
Rexahn Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
May 09, 2016 09:00 ET
|
Rexahn Pharmaceuticals, Inc.
Progresses Novel Targeted Anti-Cancer Therapies in Clinical Development Initiates Phase Ib/IIa Clinical Trial of RX-3117 and Begins Enrollment in Phase IIa Randomized Clinical Trial of...
Rexahn Pharmaceuticals Presents Clinical Trial Results for Archexin® at the 2016 American Association for Cancer Research Annual Meeting
April 20, 2016 09:02 ET
|
Rexahn Pharmaceuticals, Inc.
Data Featured at Late Breaking and Clinical Trials Session Suggest Potential Dose and Time Dependent Clinical Benefit of Archexin® in Combination with Everolimus Additional Poster Presentations on...
Rexahn Pharmaceuticals to Present at the 2016 American Association for Cancer Research Annual Meeting
April 13, 2016 11:02 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., April 13, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment...
Rexahn Pharmaceuticals Announces Initiation of Phase Ib/IIa Clinical Trial of Its Novel Oral Anti-Cancer Therapeutic RX-3117 in the Treatment of Pancreatic and Bladder Cancer
March 29, 2016 09:00 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., March 29, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation targeted therapeutics for the...
Rexahn Pharmaceuticals Presents Additional Data for Supinoxin for the Treatment of Triple Negative Breast Cancer at the 2016 Targeted Anticancer Therapeutics Congress
March 24, 2016 09:00 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., March 24, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment...